TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21262889

Group type: EXPERIMENTAL
Intervention: Chlamydia screening among women 14 to 15 years of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlamydia screening among women 20 to 21 years of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlamydia screening among women 22 to 23 years of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlamydia screening among women 24 to 25 years of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlamydia screening among Black women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlamydia screening among Hispanic women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlamydia screening among women with public insurance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlamydia screening among women with public pending insurance
Number of subjects: 0
Study: 18355218

Group type: EXPERIMENTAL
Intervention: Right from the Start (RFTS)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Home visiting (treatment as usual)
Number of subjects: 76
Study: 16931678

Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg every 12 h for 72 h postoperatively
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo every 12 h for 72 h postoperatively
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12788192

Group type: EXPERIMENTAL
Intervention: Pilocarpine 5 mg
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 11119400

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine antibiotic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of patient and physician education
Number of subjects: 0
Study: 9383115

Group type: COMPARATOR
Intervention: 30 min of cycling exercise at 60% VO2max
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cold pressor test
Number of subjects: 12
Study: 2885853

Group type: EXPERIMENTAL
Intervention: Astemizole suspension (5 ml, 1 mg/ml) once daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Terfenadine suspension (5 ml, 6 mg/ml) twice daily
Number of subjects: 65
Study: 30358153

Group type: EXPERIMENTAL
Intervention: Usual care and additional (whey) protein intake (PRO)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Usual care, additional protein intake, and supervised strength training for 18 weeks (PRO+EX)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care (CON)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Usual care, additional protein intake, and supervised strength training (PRO+EX)
Number of subjects: 76
Study: 26723801

Group type: EXPERIMENTAL
Intervention: Transitional care intervention with automated alert messages to physicians and staff
Number of subjects: 313

Group type: COMPARATOR
Intervention: Matched discharges from the previous 1.5 years (Control)
Number of subjects: 313
Study: 23410501

Group type: EXPERIMENTAL
Intervention: Back massage therapy (20 minutes session for 5 consecutive days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (received the same care without back massage)
Number of subjects: 60
Study: 22236804

Group type: EXPERIMENTAL
Intervention: Omalizumab (n = 14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional therapy (n = 16)
Number of subjects: 30
Study: 20438327

Group type: EXPERIMENTAL
Intervention: ORS with honey
Number of subjects: 100

Group type: COMPARATOR
Intervention: ORS (control)
Number of subjects: 100
Study: 19252457

Group type: EXPERIMENTAL
Intervention: Dressings with Safetac adhesive technology
Number of subjects: 0
Study: 16551151

Group type: EXPERIMENTAL
Intervention: Questionnaire-plus-implementation intention
Number of subjects: 554

Group type: COMPARATOR
Intervention: Questionnaire-only
Number of subjects: 554
Study: 13130320

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Oral diet (OD)
Number of subjects: 55
Study: 11073745

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (3 mg/kg/d)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (5 mg/kg/d)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Amphotericin B lipid complex (ABLC)
Number of subjects: 243
Study: 9361912

Group type: EXPERIMENTAL
Intervention: Aspirin (1.2 grams daily for 3 days)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight dextran (for 3 days)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 114
Study: 1312797

Group type: EXPERIMENTAL
Intervention: Mexiletine (750 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 2996726

Group type: EXPERIMENTAL
Intervention: Pindolol (5-10 mg twice a day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Propranolol (40-80 mg 4 times a day)
Number of subjects: 23
Study: 31343376

Group type: EXPERIMENTAL
Intervention: DMSO‐L (local administration)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: DMSO‐IP (intraperitoneal administration)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sham group
Number of subjects: 70
Study: 30942032

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied during the operation and within 1 month after the operation, once every other day at specific acupuncture points (Hegu, Qihai, Zhongwan, Pishu, Shenshu).
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no electroacupuncture treatment).
Number of subjects: 80
Study: 28846143

Group type: EXPERIMENTAL
Intervention: 8‐mm‐tip catheter
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 3.5‐mm open irrigation‐tip catheter
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 3.5‐mm open irrigation porous‐tip catheter
Number of subjects: 150
Study: 25744224

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM (booster dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: MenACWY-CRM (primary dose)
Number of subjects: 100
Study: 24159565

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 21512577

Group type: EXPERIMENTAL
Intervention: Two double doses of influenza vaccine over 28 days
Number of subjects: 298

Group type: COMPARATOR
Intervention: Two standard doses of influenza vaccine over 28 days
Number of subjects: 298

Group type: COMPARATOR
Intervention: Single standard dose of influenza vaccine
Number of subjects: 298
Study: 19192876

Group type: EXPERIMENTAL
Intervention: MIPO (Minimal Invasive Plating Osteosynthesis)
Number of subjects: 40

Group type: COMPARATOR
Intervention: ORPO (Open Reduction and Plating Osteosynthesis)
Number of subjects: 40
Study: 16776702

Group type: EXPERIMENTAL
Intervention: Migraineurs (patients with sleep-related migraine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (matched for age and sex)
Number of subjects: 10
Study: 14872039

Group type: EXPERIMENTAL
Intervention: Phenobarbitone (40 mg/kg as first line)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (as second line)
Number of subjects: 22
Study: 11127487

Group type: EXPERIMENTAL
Intervention: 5-day moxifloxacin 400 mg once daily
Number of subjects: 567

Group type: COMPARATOR
Intervention: 5-day azithromycin (500 mg qd x 1, then 250 mg qd x 4)
Number of subjects: 567
Study: 9324147

Group type: EXPERIMENTAL
Intervention: Enteral feeding (FEED) starting on postoperative day (POD) 1 via a jejunostomy tube, n = 12
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intravenous fluid (IVF), n = 17
Number of subjects: 29
Study: 8463437

Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 19
Study: 2412521

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate (N=5)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitor (N=9)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (initial period and two-week washout)
Number of subjects: 14
Study: 29067819

Group type: EXPERIMENTAL
Intervention: Interactive web-based intervention with 6 in-person group sessions over 12 months
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Interactive web-based intervention
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (customary care)
Number of subjects: 73
Study: 28101658

Group type: EXPERIMENTAL
Intervention: Naso-intestinal tube
Number of subjects: 46
Study: 25158287

Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (3 mg caffeine per kg body mass)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 14
Study: 23458700

Group type: EXPERIMENTAL
Intervention: Internet-based parent management training (PMT) for parents of children with conduct problems
Number of subjects: 57
Study: 21600090

Group type: EXPERIMENTAL
Intervention: Low dose chemotherapy plus valproic acid (VPA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low dose chemotherapy regimen
Number of subjects: 41
Study: 18329827

Group type: EXPERIMENTAL
Intervention: Medication clinic only
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Medication clinic plus BRENDA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Medication clinic plus cognitive behavioral therapy (CBT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 17068818

Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation (TSI)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12511312

Group type: EXPERIMENTAL
Intervention: High-dose albuterol (15 mg/hr)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Usual-dose albuterol (7.5 mg/hr)
Number of subjects: 127
Study: 10371571

Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin-2 (3 million IU/m2 twice daily for 5 days)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Intravenous interleukin-2 (12 million IU/day for 5 days)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: PEG interleukin-2 (2 million IU/m2 intravenous bolus every 2 months from week 2 to week 50)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Zidovudine and didanosine alone (control group)
Number of subjects: 94
Study: 8647056

Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunoglobulins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 0
Study: 1650528

Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy (cyclophosphamide, doxorubicin, and vincristine‐‐CAV) plus intrapleural bacillus Calmette‐Guerin (BCG) (n = 26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: adjuvant CAV alone (n = 26)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy (CAV) plus intrapleural BCG
Number of subjects: 52

Group type: COMPARATOR
Intervention: adjuvant CAV alone
Number of subjects: 52
Study: 6868628

Group type: EXPERIMENTAL
Intervention: Percutaneous high‐voltage therapy with cobalt 60 (51 patients)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ultra‐hard X‐rays from 17 MeV betatron (35 patients)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Both interventions (Cobalt 60 and Betatron)
Number of subjects: 86
Study: 29357820

Group type: EXPERIMENTAL
Intervention: Formula containing a mix of plant oils and dairy fat (D)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Only plant oils (P)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Plant oils supplemented with long-chain polyunsaturated fatty acids (PDHA)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Breastfed infants (BF)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: All formula groups (D, P, PDHA)
Number of subjects: 88
Study: 26388169

Group type: EXPERIMENTAL
Intervention: 5 mg/kg oxantel pamoate
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: 25 mg/kg oxantel pamoate
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: 30 mg/kg oxantel pamoate
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 22590991

Group type: EXPERIMENTAL
Intervention: 60 mg iron and 250 µg folate with or without 15 mg zinc
Number of subjects: 985
Study: 21501249

Group type: EXPERIMENTAL
Intervention: small bowl and small scoop
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: small bowl and large scoop
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: large bowl and small scoop
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: large bowl and large scoop
Number of subjects: 54
Study: 20075647

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 28
Study: 17620127

Group type: COMPARATOR
Intervention: cis‐9, trans‐11 CLA (CONT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cis‐9, trans‐11 CLA (NAT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: trans‐10, cis‐12 CLA and cis‐9, trans‐11 CLA (SYN)
Number of subjects: 0
Study: 16290977

Group type: EXPERIMENTAL
Intervention: Simplified education program with follow-up phone call focusing on symptom management
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study: 11902732

Group type: EXPERIMENTAL
Intervention: IFN plus Ara‐C (5 million units/m2 IFN once per day and 20 mg/m2 Ara‐C for 10 days each month)
Number of subjects: 12

Group type: COMPARATOR
Intervention: IFN alone (5 million units/m2 once per day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IFN plus Ara‐C
Number of subjects: 12

Group type: COMPARATOR
Intervention: IFN alone
Number of subjects: 12
Study: 10615742

Group type: EXPERIMENTAL
Intervention: Utah Prepaid Mental Health Plan (UPMHP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contemporaneous control group
Number of subjects: 0
Study: 8523000

Group type: EXPERIMENTAL
Intervention: Solcotrans drainage system
Number of subjects: 144

Group type: COMPARATOR
Intervention: Hemovac disposable drainage system or inadequate drainage for autotransfusion
Number of subjects: 144
Study: 1833896

Group type: EXPERIMENTAL
Intervention: Enoximone (0.5 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 0
Study: 7180894

Group type: EXPERIMENTAL
Intervention: Response-produced feedback
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Supplementary sensory feedback
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (nonretarded children)
Number of subjects: 213
Study: 31814159

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenalidomide combined with rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 30395745

Group type: EXPERIMENTAL
Intervention: Infographic
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Video
Number of subjects: 80
Study: 28438210

Group type: EXPERIMENTAL
Intervention: BKPyV
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: JCPyV
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: BKPyV and JCPyV
Number of subjects: 266
Study: 26028407

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m² every 3 weeks)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 272

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 272
Study: 24150435

Group type: EXPERIMENTAL
Intervention: Total Disc Replacement (TDR)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Multidisciplinary Rehabilitation (MDR)
Number of subjects: 173
Study: 20854196

Group type: EXPERIMENTAL
Intervention: Switching to DRV/r 800/100 mg once daily, either as monotherapy or with two NRTIs
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Discontinuation of efavirenz or zidovudine
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Routine screening of HIV-positive patients for vitamin D
Number of subjects: 256
Study: 19017758

Group type: EXPERIMENTAL
Intervention: Detemir once daily and aspart before meals (n = 67)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn (NPH) and regular insulin twice daily (n = 63)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Detemir/aspart group
Number of subjects: 130

Group type: COMPARATOR
Intervention: NPH/regular group
Number of subjects: 130
Study: 17523932

Group type: EXPERIMENTAL
Intervention: Sodium selenite 400 microg daily during 4 weeks of TL01 therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo during 4 weeks of TL01 therapy
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sodium selenite 400 microg daily
Number of subjects: 13
Study: 15050199

Group type: EXPERIMENTAL
Intervention: Primary fibromyalgia patients
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 41
Study: 10746814

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 9545915

Group type: EXPERIMENTAL
Intervention: Vitremer (resin-modified glass ionomer)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fuji II LC Improved (resin-modified glass ionomer)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dyract (polyacid-modified resin composite)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Compoglass (polyacid-modified resin composite)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomers
Number of subjects: 120
Study: 1580920

Group type: EXPERIMENTAL
Intervention: Discontinuation of parenteral antimicrobials (n=53 cases)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Continuation of parenteral therapy (n=11 cases)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (n=29 controls)
Number of subjects: 82
Study: 3884180

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (SRT)
Number of subjects: 24
Study: 2455107

Group type: EXPERIMENTAL
Intervention: Felodipine 2.5 mg b.i.d.
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg b.i.d.
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg b.i.d.
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Felodipine (all doses)
Number of subjects: 109
Study: 29843766

Group type: EXPERIMENTAL
Intervention: Bioactive glass (S53P4)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Autologous bone graft (ABG) with tricalcium phosphate
Number of subjects: 50
Study: 28253938

Group type: EXPERIMENTAL
Intervention: Intensive standardized training
Number of subjects: 56

Group type: COMPARATOR
Intervention: Minimal training
Number of subjects: 56
Study: 26669302

Group type: EXPERIMENTAL
Intervention: Contoured sandals (n = 49)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Flat flip-flops (n = 50)
Number of subjects: 150

Group type: COMPARATOR
Intervention: In-shoe orthoses (n = 51)
Number of subjects: 150
Study: 23076002

Group type: EXPERIMENTAL
Intervention: Sickle cell hemoglobin-C disease (SCC) patients with proliferative stage III‐IV‐V retinopathy (group 3)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sickle cell anemia (SCA) patients
Number of subjects: 59
Study: 21392790

Group type: EXPERIMENTAL
Intervention: Triple eradication therapy (n=16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Symptomatic therapy (n=15)
Number of subjects: 31
Study: 18501583

Group type: EXPERIMENTAL
Intervention: Intrathecal lidocaine 2% w/v
Number of subjects: 71

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine 0.5% w/v
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Relative motor blocking potency ratio
Number of subjects: 71
Study: 16531421

Group type: EXPERIMENTAL
Intervention: KH‐3500 "accommodative" IOL
Number of subjects: 28

Group type: COMPARATOR
Intervention: Softec1 IOL
Number of subjects: 28
Study: 12972722

Group type: EXPERIMENTAL
Intervention: semi-standardized acupuncture (150 patients)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: standardized minimal acupuncture (75 patients)
Number of subjects: 300

Group type: COMPARATOR
Intervention: no interval treatment for 12 weeks followed by semi-standardized acupuncture (75 patients, waiting list control)
Number of subjects: 300
Study: 10746262

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8769387

Group type: EXPERIMENTAL
Intervention: Sandostatin LAR (20 mg and 30 mg doses at 4-week intervals)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Sandostatin LAR
Number of subjects: 101
Study: 1579579

Group type: EXPERIMENTAL
Intervention: Dietary polyunsaturated fatty acids (PUFA) intake, expressed as percentage of total kilocalories.
Number of subjects: 6250

Group type: EXPERIMENTAL
Intervention: Dietary PUFA intake, expressed in absolute grams and ratios.
Number of subjects: 6250

Group type: COMPARATOR
Intervention: Usual care group (control).
Number of subjects: 6250
Study: 4074196

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fenofibrate (open-label)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fenofibrate (all analyses)
Number of subjects: 15
Study: 29498344

Group type: EXPERIMENTAL
Intervention: Elevated gut inflammation (GI) and permeability (GP) scores
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Elevated GP scores
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Higher α-1 acid glycoprotein (AGP) levels
Number of subjects: 539
Study: 29709127

Group type: EXPERIMENTAL
Intervention: Paper patching
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 24126705

Group type: EXPERIMENTAL
Intervention: House of Education education program
Number of subjects: 502

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 502
Study: 23022248

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 185
Study: 20298993

Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Coronary Intervention (PPCI)
Number of subjects: 6763

Group type: COMPARATOR
Intervention: Fibrinolysis (FL)
Number of subjects: 6763